Janux Therapeutics Inc

JANX is in a Stage 2 advancing phase with persistent higher highs and higher lows supported by rising EMAs, confirming structural bullish bias. However, price is currently extended above the 9/21 EMAs with a recent Bullish Exhaustion candle and extreme overbought readings near the declining 200 DMA, indicating short-term pullback risk. Medium-term bias remains bullish, but execution should await a pullback into the rising EMAs and prior consolidation zone for optimal entry. We recommend Stalk until a disciplined pullback interaction appears.

• ↑TRACTr platform advancing trials for JANX007 and JANX014.
• ↑Consensus Moderate Buy with 9 buys, 3 holds, 2 sells.
• ↓Removal from Russell Growth indexes may reduce investor demand.